Hereditary angioedema: a current state-of-the-art review, V: attenuated androgens for the treatment of hereditary angioedema
- PMID: 18220148
- DOI: 10.1016/s1081-1206(10)60582-0
Hereditary angioedema: a current state-of-the-art review, V: attenuated androgens for the treatment of hereditary angioedema
Abstract
Objective: To provide a summary of the literature regarding the use of attenuated androgens during the past 40 to 50 years for the treatment of hereditary angioedema (HAE).
Data sources: MEDLINE and PubMed were searched to identify studies involving the treatment of HAE with androgens.
Study selection: Studies were selected based on their relevance to the use of androgens for the treatment of HAE.
Results: Attenuated androgens have proven successful for the short- and long-term treatment of HAE. Adverse effects are still concerning, and their use in children and pregnant women must be undertaken with great caution. Scheduled monitoring of liver function tests and lipid profiles in patients treated with these medications is critical.
Conclusions: Attenuated androgens have been successful in the short- and long-term treatment of HAE, and they are still the most frequently used medications in the United States for the treatment of this disease. There is a lack of readily available options for the treatment of acute HAE attacks apart from the administration of fresh frozen plasma or safe prophylactic therapies; however, several appropriate agents currently in clinical trials in the United States appear promising.
Similar articles
-
Hereditary angiodema: a current state-of-the-art review, IV: short- and long-term treatment of hereditary angioedema: out with the old and in with the new?Ann Allergy Asthma Immunol. 2008 Jan;100(1 Suppl 2):S13-8. doi: 10.1016/s1081-1206(10)60581-9. Ann Allergy Asthma Immunol. 2008. PMID: 18220147
-
Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients.Ann Allergy Asthma Immunol. 2008 Feb;100(2):153-61. doi: 10.1016/S1081-1206(10)60424-3. Ann Allergy Asthma Immunol. 2008. PMID: 18320917
-
Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.Allergy Asthma Proc. 2012 May-Jun;33(3):235-40. doi: 10.2500/aap.2012.33.3573. Allergy Asthma Proc. 2012. PMID: 22584192 Review.
-
C1-inhibitor concentrate for individual replacement therapy in patients with severe hereditary angioedema refractory to danazol prophylaxis.Transfusion. 2009 Sep;49(9):1987-95. doi: 10.1111/j.1537-2995.2009.02230.x. Epub 2009 May 20. Transfusion. 2009. PMID: 19497056 Clinical Trial.
-
HAE update: determining optimal patient specific therapy.Allergy Asthma Proc. 2013 Jan-Feb;34(1):7-12. doi: 10.2500/aap.2013.34.3624. Allergy Asthma Proc. 2013. PMID: 23406928 Review.
Cited by
-
Management of upper airway edema caused by hereditary angioedema.Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):19. doi: 10.1186/1710-1492-6-19. Allergy Asthma Clin Immunol. 2010. PMID: 20667122 Free PMC article.
-
Pediatric hereditary angioedema.Pediatr Allergy Immunol. 2014 Aug;25(5):420-7. doi: 10.1111/pai.12168. Epub 2013 Dec 9. Pediatr Allergy Immunol. 2014. PMID: 24313851 Free PMC article. Review.
-
2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema.Allergy Asthma Clin Immunol. 2010 Jul 28;6(1):24. doi: 10.1186/1710-1492-6-24. Allergy Asthma Clin Immunol. 2010. PMID: 20667127 Free PMC article.
-
Hereditary angioedema therapy: kallikrein inhibition and bradykinin receptor antagonism.World Allergy Organ J. 2010 Sep;3(9 Suppl):S34-8. doi: 10.1097/WOX.0b013e3181f20dbc. World Allergy Organ J. 2010. PMID: 23282868 Free PMC article.
-
Current and emerging management options for hereditary angioedema in the US.Drugs. 2008;68(18):2561-73. doi: 10.2165/0003495-200868180-00003. Drugs. 2008. PMID: 19093699 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous